Axsome stock skyrocketed to a record high Thursday after the FDA approved Auvelity for agitation due to Alzheimer's disease.

By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Axsome Therapeutics (AXSM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports ...

Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by 15 ...

Several KOLs have highlighted concerns over cost with Symbravo, since fixed-dose combination (FDC) drugs tend to be expensive ...

If you are wondering whether Axsome Therapeutics at around US$178 per share still offers value, you are not alone in asking what the current price really reflects. The stock has seen a 4.9% return ...

Axsome Therapeutics (NASDAQ: AXSM) isn't one of the more famous or prominent biotech companies, but investors interested in the industry had better get to know this drugmaker. Not only has Axsome ...

Axsome Therapeutics AXSM is preparing to release its quarterly earnings on Monday, 2025-08-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million. Auvelity (oral ...

Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to ...